In summary, our findings illuminate the vulnerability of cancer patients to drug resistance, which is particularly evident in the increased expression of ABCB1 and CYP1B1 in tumor samples from the poor-responders category, along with the associated molecular pathways. This evidence concerns the gene CYP1B1 and cancer.